Scarpellini E, Lupo M, Iegri C, Gasbarrini A, De Santis A, Tack J
Translational Research Center for Gastrointestinal Diseases (T.A.R.G.I.D.), KULeuven, Herestraat 49, 3000, Leuven.
Rev Recent Clin Trials. 2014;9(3):141-7. doi: 10.2174/1574887109666141216104334.
The gut-liver axis model has helped to explain the liver steatosis (NAFLD) and steatohepatitis (NASH) etiopathogenesis. The discovery of a key role for an altered intestinal permeability (IP) in this pathophysioligcal framework has closed the link between gut lumen antigenic/toxic substances and systemic and liver inflammation in NAFLD and obesity, metabolic syndrome. Recent evidence from the literature show how IP can be modulated by several non-pharmacological and pharmacological agents and be the target for future preventive and curative treatment of NAFLD and NASH. In this review we describe the concept of IP, its ultrastructural basis, its role in the NALFD pathophysiology and emerging evidence on non-pharmacological and pharmacological agents able to favourably modulate it.
肠-肝轴模型有助于解释肝脂肪变性（非酒精性脂肪性肝病，NAFLD）和脂肪性肝炎（非酒精性脂肪性肝炎，NASH）的发病机制。在这一病理生理框架中，肠道通透性（IP）改变的关键作用被发现，这揭示了肠道腔内抗原性/毒性物质与NAFLD、肥胖及代谢综合征中的全身炎症和肝脏炎症之间的联系。文献中的最新证据表明，IP可被多种非药物和药物制剂调节，并且是未来NAFLD和NASH预防及治疗的靶点。在本综述中，我们描述了IP的概念、其超微结构基础、其在NAFLD病理生理学中的作用，以及关于能够有利地调节IP的非药物和药物制剂的新证据。
